Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US9018201B2 · kind B2 · utility
7Cited by
12References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 21, 2013 |
| Grant date | Apr 28, 2015 |
| Priority date | — |
| Expiry date | Aug 21, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61N2005/1098
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound having the structure set forth in Formula (I) and Formula (II):wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.